The short answer
Tang and colleagues examined cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity using target trial emulation, published in Diabetes, Obesity and Metabolism in November 2025. It is observational data analysed with trial-like discipline, not a randomised trial.
Key facts
- Study
- Tang 2025, Diabetes Obes Metab (PMID 40874398)
- Design
- Target trial emulation
- Data source
- Observational records
- Population
- Adults with obesity
- Outcomes
- Cardiovascular and kidney
- Randomised
- No
Why this question needed a method like this
Cardiovascular and kidney outcomes accumulate over years. A randomised trial powered to detect differences in them requires very large numbers followed for a long time, at enormous cost. Emulation applied to existing records offers an earlier reading, and that is why this design is appearing across the incretin literature.
What the design permits
A comparison constructed to avoid the biases that arise from analytical choices (immortal time, prevalent user selection, misaligned follow-up). Where the target trial is specified in advance and time zero is properly aligned, the result is substantially more trustworthy than a conventional retrospective analysis.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What it does not permit
Causal certainty. People prescribed a GLP-1 receptor agonist differ from those not prescribed one in ways records capture only partly: health engagement, access, unmeasured severity, concurrent care. Those differences remain in the comparison, and no design applied after the fact removes them.
How this sits beside the randomised evidence
Randomised cardiovascular outcome trials exist for individual incretins and remain the stronger evidence for those specific compounds. Emulation studies cover broader populations and longer follow-up than trials manage, at lower evidential weight. Both are useful and they are not interchangeable, which is the distinction most reporting collapses.
The parallel finding in heart failure
Lin and colleagues applied the same approach to tirzepatide in heart failure with preserved ejection fraction, published in Nature Communications in May 2025. Two independent emulation studies on incretin outcomes in one year indicates the method is becoming standard for these questions rather than exceptional.
What none of it concerns
Research material. These studies examine licensed medicines prescribed and monitored clinically, in defined patient populations. Nothing supplied here is a GLP-1 receptor agonist, is covered by these findings, or is an alternative to a prescribed medicine.
Frequently asked questions
Is this randomised evidence?
No. It is observational data analysed using target trial emulation, which removes design-induced biases but cannot balance unmeasured factors.
Why not just run a randomised trial?
Cardiovascular and kidney outcomes accumulate over years, requiring very large, very long and very expensive trials.
Does it replace the randomised outcome trials?
No. Those remain stronger for the specific compounds they studied. Emulation covers broader populations at lower evidential weight.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Tirzepatide in Heart Failure With Preserved Ejection FractionA target trial emulation in Nature Communications examined tirzepatide in HFpEF. Why this population is studied and what the design supports.
- The Correction Nobody ReadsThe aleniglipron Phase 2b carries a publisher correction. So does the survodutide comparison. Checking for one is a step almost everyone skips.
- Amycretin's Move to Phase 3Novo Nordisk advanced amycretin to Phase 3 in 2026 on the strength of a Lancet phase 1b/2a. What that early trial was, and what it was not.
- REDEFINE 4: The Head-to-Head Novo Nordisk Lost809 adults, 84 weeks, open-label. CagriSema reached 23.0% against tirzepatide's 25.5% and did not meet its non-inferiority endpoint.
- CagriSema After REDEFINE 4A failed head-to-head does not block an approval. What regulators actually assess, and what changed for CagriSema in February 2026.